Back to top
more

West Pharmaceutical Services (WST)

(Real Time Quote from BATS)

$329.61 USD

329.61
309,963

+14.84 (4.72%)

Updated Nov 5, 2024 12:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks News

Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates

Exact Sciences' (EXAS) legacy Screening business registered an improvement in revenues during the third quarter on strong contributions from Cologuard volume growth.

Myriad Genetics (MYGN) Q3 Loss Wider Than Expected, Revenues Top

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment drove Q3 sales despite a challenging business environment.

PacBio's (PACB) Q3 Earnings Miss Estimates, Revenues Top

PacBio (PACB) sees strength in Q3 product revenues, led by robust consumable and instrument sales.

Catalent (CTLT) Q1 Earnings Top Estimates, FY22 View Up

Catalent's (CTLT) robust performance across most of its segments drives its first-quarter fiscal 2022 top line.

Henry Schein (HSIC) Q3 Earnings Top Estimates, 2021 EPS View Up

Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the third quarter.

IDEXX (IDXX) Q3 Earnings Beat Estimates, Gross Margin Falls

IDEXX's (IDXX) Q3 top line rides on strong sales at the CAG and Water businesses.

Bruker (BRKR) Q3 Earnings Surpass Estimates, Margins Up

Bruker (BRKR) reports better-than-expected earnings and revenues for the third quarter of 2021 on geographical performance driving the top line.

McKesson (MCK) Earnings and Revenues Beat Estimates in Q2

McKesson's (MCK) fiscal second-quarter 2022 results benefit from substantial growth in the Medical-Surgical Solutions business.

Hologic (HOLX) Q4 Earnings Surpass Estimates, 2022 View Dull

Impressive performance by the Breast Health and GYN Surgical segments drives Hologic's (HOLX) fiscal fourth-quarter revenues.

NextGen Healthcare (NXGN) Gains 9.7% Since Q2 Earnings Beat

NextGen Healthcare's (NXGN) fiscal second-quarter earnings reflect strong segmental performance.

Chemed (CHE) Q3 Earnings Beat Estimates, Full-Year EPS View Up

Chemed (CHE) reports better-than-expected earnings and revenues in the third-quarter 2021, with a solid performance by the Roto-Rooter segment driving the top line.

OPKO Health's (OPK) Q3 Earnings, Revenues Top Estimates

OPKO Health's (OPK) third-quarter results benefit from strength in its Pharmaceuticals segment, backed by robust RAYALDEE sales.

Integer Holdings (ITGR) Beats on Q3 Earnings, Ups 2021 EPS View

Integer Holdings' (ITGR) third-quarter results reflect robust segmental performances along with strength in the majority of the product lines.

Merit Medical's (MMSI) Q3 Earnings, Revenues Top Estimates

Merit Medical (MMSI), in the third quarter, benefits from revenue growth in its Cardiovascular segment, and from the majority of the product categories within its Cardiovascular unit.

Cerner (CERN) Q3 Earnings and Revenues Surpass Estimates

Cerner's (CERN) third-quarter results benefit from gains across four of its business units.

Bio-Rad (BIO) Q3 Earnings Surpass Estimates, 2021 View Raised

Strength in the Life Science and Clinical Diagnostics segments drove Bio-Rad's (BIO) revenues in the third quarter.

DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates

DexCom's (DXCM) third-quarter results benefit from domestic and international revenue growth and solid new customer additions.

Stryker (SYK) Earnings and Revenues Miss Estimates in Q3

Despite pandemic-led disruptions, Stryker's (SYK) third-quarter earnings reflect strong performance across Orthopaedics, MedSurg and Neurotechnology and Spine segments.

ResMed (RMD) Q1 Earnings Top Estimates, Margins Decline

ResMed (RMD) reports better-than-expected earnings and revenues with robust demand for sleep and respiratory care devices driving Q1 top line.

DaVita (DVA) Beats on Q3 Earnings, Narrows 2021 EPS View

DaVita's (DVA) strength in dialysis patient service revenues drives its Q3 top line.

Teleflex (TFX) Q3 Earnings Top Estimates, Full-Year EPS View Up

Teleflex (TFX) reports better-than-expected earnings and revenues with strong geographical performance driving the top line in third-quarter 2021.

West Pharmaceutical (WST) Q3 Earnings & Revenues Beat Estimates

West Pharmaceutical's (WST) third-quarter earnings reflect segmental strong performance.

West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates

West Pharmaceutical (WST) delivered earnings and revenue surprises of 13.19% and 3.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for West Pharmaceutical Services (WST) This Earnings Season?

West Pharmaceutical Services (WST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?

Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q4 sales.